pGL3 2 kb prom. CD274 Citations (3)

Originally described in: Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Coelho MA, de Carne Trecesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J Immunity. 2017 Dec 19;47(6):1083-1099.e6. doi: 10.1016/j.immuni.2017.11.016. Epub 2017 Dec 12. PubMed Journal

---

Articles Citing pGL3 2 kb prom. CD274

Articles
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Yan Y, Zheng L, Du Q, Yan B, Geller DA. Cancer Immunol Immunother. 2020 Sep;69(9):1891-1903. doi: 10.1007/s00262-020-02586-9. Epub 2020 May 6. PubMed
Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Deng Y, Xia X, Zhao Y, Zhao Z, Martinez C, Yin W, Yao J, Hang Q, Wu W, Zhang J, Yu Y, Xia W, Yao F, Zhao D, Sun Y, Ying H, Hung MC, Ma L. Nat Commun. 2021 Dec 6;12(1):7041. doi: 10.1038/s41467-021-27349-7. PubMed
FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD-L1 Expression and Cell Proliferation. Madhi H, Lee JS, Choi YE, Li Y, Kim MH, Choi Y, Goh SH. Adv Sci (Weinh). 2022 Oct;9(29):e2202702. doi: 10.1002/advs.202202702. Epub 2022 Aug 17. PubMed

If you have published an article using this material, please email us at to have your article added to this page.